Skip to content
Assyro AI
US FDA source recordTA · Tentative Approval Letter

RUXOLITINIB — FDA Tentative Approval Letter (ANDA 208869)

Issued to APOTEX INC. Application meets requirements but marketing is blocked (patent/exclusivity).

Issued

July 22, 2026

Application

ANDA 505j • 208869

Product

RUXOLITINIB

Company

APOTEX INC

Stage

Final Decision

Read source documentView similar TA records

Assyro regulatory brief

Free

What did FDA decide for RUXOLITINIB?

Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.

Verify in source

Source facts

FDA issued a tentative approval letter for RUXOLITINIB on 2026-07-22. The source metadata identifies ANDA 208869 as an original application. Review the exact FDA letter for the approved conditions and labeling.

Key details in this letter

  • 1FDA action: tentative approval.
  • 2Application: ANDA 208869.
  • 3Submission: original application.
  • 4Sponsor: APOTEX INC.

Suggested next step

Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.

Open the document workspace

Built from structured FDA metadata and deterministic source-text signals. Topic matches are navigation aids, not legal or regulatory conclusions. Verify material decisions against the original FDA document.

FDAPDFUpdated Jul 30, 2026

FDA source document

Read the full FDA tentative approval letter (PDF)

Loading document viewer…

Common questions about the RUXOLITINIB tentative approval letter

Is RUXOLITINIB FDA approved?

Not for marketing yet. FDA granted tentative approval to ANDA 208869 for RUXOLITINIB on July 22, 2026, meaning the application meets approval standards but patent or exclusivity protections block final approval. The product cannot be marketed until those conditions resolve and FDA issues final approval.

What is ANDA 208869?

ANDA 208869 is the application under which FDA issued this tentative approval letter for RUXOLITINIB to APOTEX INC. The letter is dated July 22, 2026.

What happens after an FDA tentative approval letter?

The product cannot be marketed yet. Tentative approval means the application meets FDA approval standards, but patent or exclusivity protections block final approval. The sponsor typically requests final approval as the blocking date approaches, and FDA re-verifies that the approval conditions still hold before granting it.